Compare OXSQ & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OXSQ | AARD |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 135.7M | 107.7M |
| IPO Year | 2003 | 2025 |
| Metric | OXSQ | AARD |
|---|---|---|
| Price | $1.28 | $5.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | ★ 1.3M | 122.1K |
| Earning Date | 04-29-2026 | 05-14-2026 |
| Dividend Yield | ★ 22.83% | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ 0.10 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.61 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.05 | $3.35 |
| 52 Week High | $2.05 | $17.94 |
| Indicator | OXSQ | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 47.69 |
| Support Level | $1.24 | $5.47 |
| Resistance Level | $1.96 | $6.01 |
| Average True Range (ATR) | 0.03 | 0.54 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 22.22 | 61.72 |
Oxford Square Capital Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize portfolio's total return. Its primary current focus is to seek an attractive risk-adjusted total return by investing in corporate debt securities and, to a lesser extent collateralized loan obligation (CLO) structured finance investments that own corporate debt securities. CLO investments may also include warehouse facilities, which are early-stage CLO vehicles intended to aggregate loans that may be used to form the basis of a traditional CLO vehicle. The company may also invest in publicly traded debt and/or equity securities.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.